{"id":520547,"date":"2021-07-29T22:03:16","date_gmt":"2021-07-30T02:03:16","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/omega-therapeutics-announces-pricing-of-initial-public-offering\/"},"modified":"2021-07-29T22:03:16","modified_gmt":"2021-07-30T02:03:16","slug":"omega-therapeutics-announces-pricing-of-initial-public-offering","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/omega-therapeutics-announces-pricing-of-initial-public-offering\/","title":{"rendered":"Omega Therapeutics Announces Pricing of Initial Public Offering"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"xn-location\">CAMBRIDGE, Mass<\/span>, <span class=\"xn-chron\">July 29, 2021<\/span> \/PRNewswire\/ &#8212; Omega Therapeutics, Inc. (Nasdaq: OMGA) (&#8220;Omega&#8221;), a development-stage biotechnology company leveraging its OMEGA Epigenomic Programming\u2122 platform to harness the power of epigenetics to develop a new class of DNA-sequence-targeting, mRNA-encoded programmable epigenetic medicines, today announced the pricing of its initial public offering of 7,400,000 shares of its common stock at a price to the public of <span class=\"xn-money\">$17.00<\/span> per share. All of the shares of common stock are being offered by Omega. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by Omega, are expected to be approximately <span class=\"xn-money\">$125.8 million<\/span>, excluding any exercise of the underwriters&#8217; option to purchase additional shares. Omega&#8217;s common stock is expected to begin trading on the Nasdaq Global Select Market under the ticker symbol &#8220;OMGA&#8221; on <span class=\"xn-chron\">July 30, 2021<\/span>. The offering is expected to close on <span class=\"xn-chron\">August 3, 2021<\/span>, subject to satisfaction of customary closing conditions. In addition, Omega has granted the underwriters a 30-day option to purchase up to an additional 1,110,000 shares of common stock at the initial public offering price less underwriting discounts and commissions.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/1395202\/Omega_Therapeutics_Logo.html\" target=\"_blank\" rel=\"nofollow noopener\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/1395202\/Omega_Therapeutics_Logo.jpg\" title=\"(PRNewsfoto\/Omega Therapeutics)\" alt=\"(PRNewsfoto\/Omega Therapeutics)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>Goldman Sachs &amp; Co. LLC,\u00a0Jefferies LLC and Piper Sandler\u00a0are\u00a0acting\u00a0as\u00a0joint\u00a0book-running\u00a0managers\u00a0of\u00a0the\u00a0offering. Wedbush PacGrow is acting as lead manager.<\/p>\n<p>A registration statement on Form S-1 (File No. 333-257794) relating to the offering has been filed with the Securities and Exchange Commission and\u00a0became effective on <span class=\"xn-chron\">July 29, 2021<\/span>. The offering is being made only by means of a prospectus. Copies of the final prospectus relating to the offering\u00a0may be obtained from: Goldman Sachs &amp; Co. LLC, Attn: Prospectus Department, 200 West Street, <span class=\"xn-location\">New York, NY<\/span> 10282, by telephone at (866) 471-2526 or by email at <a target=\"_blank\" href=\"mailto:prospectus-ny@ny.email.gs.com\" rel=\"nofollow noopener\">prospectus-ny@ny.email.gs.com<\/a>; Jefferies LLC, Attn: Equity Syndicate Prospectus Department, 520 Madison Avenue, <span class=\"xn-location\">New York, NY<\/span> 10022, by phone at (877) 821-7388, or by email at <a target=\"_blank\" href=\"mailto:Prospectus_Department@Jefferies.com\" rel=\"nofollow noopener\">Prospectus_Department@Jefferies.com<\/a>; or <span class=\"xn-person\">Piper Sandler<\/span> &amp; Co., Attn: Prospectus Department, 800 Nicollet Mall, J12S03, <span class=\"xn-location\">Minneapolis, MN<\/span> 55402, by telephone at (800) 747-3924 or by email at <a target=\"_blank\" href=\"mailto:prospectus@psc.com\" rel=\"nofollow noopener\">prospectus@psc.com<\/a>.<\/p>\n<p>This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.<\/p>\n<p>Investor contact: <br \/><span class=\"xn-person\">Joseph Rayne<\/span><br \/>Argot Partners<br \/>212.600.1902<br \/><a target=\"_blank\" href=\"mailto:ArgotOmega@argotpartners.com\" rel=\"nofollow noopener\">ArgotOmega@argotpartners.com<\/a><\/p>\n<p>Media contact: <br \/><span class=\"xn-person\">David Rosen<\/span><br \/>Argot Partners<br \/>212.600.1902<br \/><a target=\"_blank\" href=\"mailto:david.rosen@argotpartners.com\" rel=\"nofollow noopener\">david.rosen@argotpartners.com<\/a><\/p>\n<p>\u00a0<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder2\"><\/div>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=NE59864&amp;sd=2021-07-29\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/omega-therapeutics-announces-pricing-of-initial-public-offering-301344870.html\">https:\/\/www.prnewswire.com\/news-releases\/omega-therapeutics-announces-pricing-of-initial-public-offering-301344870.html<\/a><\/p>\n<p>SOURCE  Omega Therapeutics<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=NE59864&amp;Transmission_Id=202107292159PR_NEWS_USPR_____NE59864&amp;DateId=20210729\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire CAMBRIDGE, Mass, July 29, 2021 \/PRNewswire\/ &#8212; Omega Therapeutics, Inc. (Nasdaq: OMGA) (&#8220;Omega&#8221;), a development-stage biotechnology company leveraging its OMEGA Epigenomic Programming\u2122 platform to harness the power of epigenetics to develop a new class of DNA-sequence-targeting, mRNA-encoded programmable epigenetic medicines, today announced the pricing of its initial public offering of 7,400,000 shares of its common stock at a price to the public of $17.00 per share. All of the shares of common stock are being offered by Omega. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by Omega, are expected to be approximately $125.8 million, excluding any exercise of the underwriters&#8217; option to purchase additional shares. Omega&#8217;s common stock &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/omega-therapeutics-announces-pricing-of-initial-public-offering\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Omega Therapeutics Announces Pricing of Initial Public Offering&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-520547","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Omega Therapeutics Announces Pricing of Initial Public Offering - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/omega-therapeutics-announces-pricing-of-initial-public-offering\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Omega Therapeutics Announces Pricing of Initial Public Offering - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire CAMBRIDGE, Mass, July 29, 2021 \/PRNewswire\/ &#8212; Omega Therapeutics, Inc. (Nasdaq: OMGA) (&#8220;Omega&#8221;), a development-stage biotechnology company leveraging its OMEGA Epigenomic Programming\u2122 platform to harness the power of epigenetics to develop a new class of DNA-sequence-targeting, mRNA-encoded programmable epigenetic medicines, today announced the pricing of its initial public offering of 7,400,000 shares of its common stock at a price to the public of $17.00 per share. All of the shares of common stock are being offered by Omega. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by Omega, are expected to be approximately $125.8 million, excluding any exercise of the underwriters&#8217; option to purchase additional shares. Omega&#8217;s common stock &hellip; Continue reading &quot;Omega Therapeutics Announces Pricing of Initial Public Offering&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/omega-therapeutics-announces-pricing-of-initial-public-offering\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-30T02:03:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/1395202\/Omega_Therapeutics_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/omega-therapeutics-announces-pricing-of-initial-public-offering\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/omega-therapeutics-announces-pricing-of-initial-public-offering\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Omega Therapeutics Announces Pricing of Initial Public Offering\",\"datePublished\":\"2021-07-30T02:03:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/omega-therapeutics-announces-pricing-of-initial-public-offering\\\/\"},\"wordCount\":433,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/omega-therapeutics-announces-pricing-of-initial-public-offering\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1395202\\\/Omega_Therapeutics_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/omega-therapeutics-announces-pricing-of-initial-public-offering\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/omega-therapeutics-announces-pricing-of-initial-public-offering\\\/\",\"name\":\"Omega Therapeutics Announces Pricing of Initial Public Offering - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/omega-therapeutics-announces-pricing-of-initial-public-offering\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/omega-therapeutics-announces-pricing-of-initial-public-offering\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1395202\\\/Omega_Therapeutics_Logo.jpg\",\"datePublished\":\"2021-07-30T02:03:16+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/omega-therapeutics-announces-pricing-of-initial-public-offering\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/omega-therapeutics-announces-pricing-of-initial-public-offering\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/omega-therapeutics-announces-pricing-of-initial-public-offering\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1395202\\\/Omega_Therapeutics_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1395202\\\/Omega_Therapeutics_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/omega-therapeutics-announces-pricing-of-initial-public-offering\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Omega Therapeutics Announces Pricing of Initial Public Offering\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Omega Therapeutics Announces Pricing of Initial Public Offering - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/omega-therapeutics-announces-pricing-of-initial-public-offering\/","og_locale":"en_US","og_type":"article","og_title":"Omega Therapeutics Announces Pricing of Initial Public Offering - Market Newsdesk","og_description":"PR Newswire CAMBRIDGE, Mass, July 29, 2021 \/PRNewswire\/ &#8212; Omega Therapeutics, Inc. (Nasdaq: OMGA) (&#8220;Omega&#8221;), a development-stage biotechnology company leveraging its OMEGA Epigenomic Programming\u2122 platform to harness the power of epigenetics to develop a new class of DNA-sequence-targeting, mRNA-encoded programmable epigenetic medicines, today announced the pricing of its initial public offering of 7,400,000 shares of its common stock at a price to the public of $17.00 per share. All of the shares of common stock are being offered by Omega. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by Omega, are expected to be approximately $125.8 million, excluding any exercise of the underwriters&#8217; option to purchase additional shares. Omega&#8217;s common stock &hellip; Continue reading \"Omega Therapeutics Announces Pricing of Initial Public Offering\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/omega-therapeutics-announces-pricing-of-initial-public-offering\/","og_site_name":"Market Newsdesk","article_published_time":"2021-07-30T02:03:16+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/1395202\/Omega_Therapeutics_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/omega-therapeutics-announces-pricing-of-initial-public-offering\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/omega-therapeutics-announces-pricing-of-initial-public-offering\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Omega Therapeutics Announces Pricing of Initial Public Offering","datePublished":"2021-07-30T02:03:16+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/omega-therapeutics-announces-pricing-of-initial-public-offering\/"},"wordCount":433,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/omega-therapeutics-announces-pricing-of-initial-public-offering\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1395202\/Omega_Therapeutics_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/omega-therapeutics-announces-pricing-of-initial-public-offering\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/omega-therapeutics-announces-pricing-of-initial-public-offering\/","name":"Omega Therapeutics Announces Pricing of Initial Public Offering - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/omega-therapeutics-announces-pricing-of-initial-public-offering\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/omega-therapeutics-announces-pricing-of-initial-public-offering\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1395202\/Omega_Therapeutics_Logo.jpg","datePublished":"2021-07-30T02:03:16+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/omega-therapeutics-announces-pricing-of-initial-public-offering\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/omega-therapeutics-announces-pricing-of-initial-public-offering\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/omega-therapeutics-announces-pricing-of-initial-public-offering\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/1395202\/Omega_Therapeutics_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/1395202\/Omega_Therapeutics_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/omega-therapeutics-announces-pricing-of-initial-public-offering\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Omega Therapeutics Announces Pricing of Initial Public Offering"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/520547","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=520547"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/520547\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=520547"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=520547"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=520547"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}